Sandoz Henlius Expand Biosimilars Alliance to Ten Assets

6 sourcesUpdated Aug 17, 2026

Shanghai Henlius Biotech and Sandoz announced a strategic collaboration to develop and commercialize up to 10 monoclonal antibody and antibody-drug conjugate biosimilars, with Henlius handling development and manufacturing and Sandoz gaining exclusive commercialization rights outside China. The initial bundle includes cetuximab, evolocumab, belimumab biosimilars, with an option for an additional asset and an initial three products already agreed. The deal is milestone-based, potentially totaling up to 322 million, with invoiced amounts in 2026 expected to reach as much as 100.5 million. The arrangement deepens their existing oncology biosimilars partnership and expands Sandoz's pipeline from 39 to as many as 46 assets. The collaboration aims to address high-burden diseases and broaden patient access to cost-effective biologics amid looming biosimilar loss-of-exclusivity over the next decade. The deal reinforces Henlius as a key upstream supplier while Sandoz strengthens its global biosimilar footprint and market leadership.

In this story:Novartis

Where do you stand?

Novartis

How it spread

Broke pluang.com · Aug 17, 12:00 AMCenter +4h6 sources +6h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Coverage

ReutersCenterSandoz to license three biosimilar drugs from Shanghai Henlius Biotech

biopharmaapac.comOtherHenlius, Sandoz Expand Global Biosimilars Alliance with Up to 10 New Antibody Assets

tipranks.comOtherSandoz expands biosimilar pipeline with major Henlius collaboration

More on this story

Back to News

Vir Biotechnology appoints Brent Sabatini Interim CFO

Vir Biotechnology named Brent Sabatini as interim principal financial officer after Jason O’Byrne’s departure, with O’Byrne remaining through August 3 to ensure a smooth transition and a search for a permanent CFO underway. Sabatini, currently SVP and Chief Accounting Officer, brings more than two decades of finance and accounting experience and is expected to maintain continuity in financial oversight during the leadership change.

6 sources

Photo: Indian — Wikimedia Commons / Wikimedia Commons

Akums plans acquisition of Oriflame India's manufacturing assets

Akums Drugs and Pharmaceuticals will acquire Oriflame India's manufacturing business for ₹56 crore through its subsidiary Pure and Cure Healthcare, gaining two plants in Roorkee and Noida plus a Noida warehouse and immediate capacity to produce skincare, haircare, and color cosmetics as it diversifies beyond pharmaceutical manufacturing, with completion expected by August 31, 2026. The move signals a strategic shift into the fast-growing beauty and personal care sector and could open opportunities for both domestic and export opportunities leveraging Halal certifications and European machinery.